Security key
25253X207
DiaMedica Therapeutics Inc. - Voting Common Shares, no par value (DMAC)
CUSIP: 25253X207
Q3 2024 13F Holders as of 30 Sep 2024
- Security type / class
- Equity / Voting Common Shares, no par value
- Total 13F shares
- 5,580,411
- Total 13F value
- $23,326,555
- Share change
- +514,232
- Put/Call ratio
- 2.4%
- SEC-reported price per share
- $4.19
- Number of holders
- 40
- Value change
- +$2,250,136
- Number of buys
- 21
- Number of sells
- 9
- Shares outstanding
- 52,272,727
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2024
Institutions
40
Top holders
10
DMAC full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q4 2024
Previous quarter: Q2 2024
DiaMedica Therapeutics Inc. SEC filings
DiaMedica Therapeutics Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 25253X207
Recent filing periods:
Ownership snapshot
Top reported holders of DMAC - DiaMedica Therapeutics Inc. - Voting Common Shares, no par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Leon G. Cooperman
Disclosed value leader
Leon G. Cooperman
Comparable rows
15/15
Latest evidence
30 Jun 2024
13F
Lead comparable stake: 2.7%
Showing 1-6 of 15 holder rows.
Quick read
Leon G. Cooperman leads the comparable SEC ownership view at 2.7%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Leon G. Cooperman's linked filing trail.
Comparable ownership
Top 5
Leon G. Cooperman
2.7%
VANGUARD GROUP INC
1.9%
FIRST MANHATTAN CO. LLC.
1.6%
PARAGON ASSOCIATES & PARAGON ASSO...
0.92%
Bleichroeder LP
0.73%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Leon G. Cooperman |
13F
Individual
|
2.7%
|
$4,130,000
1,400,000 shares
|
— | 30 Jun 2024 |
| VANGUARD GROUP INC |
13F
Company
|
1.9%
|
$3,001,336
1,017,402 shares
|
— | 30 Jun 2024 |
| FIRST MANHATTAN CO. LLC. |
13F
Company
|
1.6%
|
$2,475,289
839,081 shares
|
— | 30 Jun 2024 |
| PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE |
13F
Company
|
0.92%
|
$1,423,711
482,614 shares
|
— | 30 Jun 2024 |
| Bleichroeder LP |
13F
Company
|
0.73%
|
$1,127,835
382,317 shares
|
— | 30 Jun 2024 |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
Company
|
0.45%
|
$698,996
236,888 shares
|
— | 30 Jun 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2024
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
40
Shares
5,580,411
Rows available
40
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2024 vs Q2 2024 Across Filers
Q2 2024 holders
32
Q3 2024 holders
40
Holder diff
8
| Investor | Q2 2024 Shares | Q3 2024 Shares | Share Diff | Share Chg % | Q2 2024 value | Q3 2024 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend